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Abstract: Metformin is the first-choice drug in uncomplicated type 2 diabetes (T2DM) and
is effective in improving glycaemic control. It is the most widely prescribed oral antidiabetic
medicine and has a good safety profile. However, there is an abundance of evidence that
metformin use is associated with decreased Vitamin B12 status, though the clinical implica-
tions of this in terms of increased risk of diabetic peripheral neuropathy are debated. There is
growing evidence that other B vitamins, vitamin D and magnesium may also be impacted by
metformin use in addition to alterations to the composition of the microbiome, depending on
the dose and duration of therapy. Patients using metformin for prolonged periods may,
therefore, need initial screening with intermittent follow-up, particularly since vitamin B12
deficiency has similar symptoms to diabetic neuropathy which itself affects 40–50% of
patients with T2DM at some stage. Among patients with T2DM, 40% are reported to
experience symptomatic gastroesophageal reflux disease (GORD), of whom 70% use oral
antidiabetic medications. The most common medications used to treat GORD are proton
pump inhibitors (PPIs) and antagonists of histamine selective H2 receptors (H2RAs), both of
which independently affect vitamin B12 and magnesium status. Research indicates that co-
prescribing metformin with either PPIs or H2RAs can have further deleterious effects on
vitamin B12 status. Vitamin B12 deficiency related to metformin and polypharmacy is likely
to contribute to the symptoms of diabetic neuropathy which may frequently be under-
recognised. This review explores current knowledge surrounding these issues and suggests
treatment strategies such as supplementation.
Keywords: H2 antagonists, diabetes, neuropathy, folic acid, magnesium, microbiome
Introduction
Diabetes has a global impact on health, with 415 million known adult cases, of which
91% have type 2 diabetes (T2DM).1 The prevalence and cost of diabetes are increasing
and contribute significantly to total national healthcare costs, accounting for 10% of the
entire National Health Service budget in the UK.2 For example, in 2017, in the US, it
was estimated that the total cost of diagnosed diabetes was $245 billion. Of this sum,
$176 billion was assigned to direct medical charges and $69 billion to productivity
losses. This represented a 41% increase from the 2012 estimate of $174 billion.
Furthermore, a diagnosis of diabetes, results on average, in medical expenditures that
are approximately 2.3 times more than those typically incurred in its absence.1
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T2DM is a chronic, complex and heterogeneous con-
dition. It is one that has numerous pathophysiological
abnormalities, with a varying predisposition to complica-
tions and an assorted clinical response to therapeutic inter-
vention. It requires ongoing medical supervision, with
a high degree of self-management to monitor blood glu-
cose levels, blood pressure and lipid profiles. It also neces-
sitates multifactorial strategies to minimise the risk of
possible acute and long-term complications such as neuro-
pathy, retinopathy, and nephropathy and cardiovascular
morbidities which are increased two-to-threefold in these
patients and are subsequently a major cause of death.3
Peripheral neuropathy is a common complication of both
T1DM and T2DM, and in 40–50% of these individuals,
a detectable condition develops within a decade of diag-
nosis of the primary condition. Commonly, it initially
presents as a loss of sensation which can develop into
neuropathic ulcers, and ultimately result in amputation.
Patients frequently experience distressing and chronic neu-
ropathic pain and paresthesia which can severely limit
quality of life 4 and are thought to account for 27% of
the medical costs associated with diabetes.5
Metformin is a first-line medication typically used in
T2DM treatment, particularly in patients who are over-
weight or obese.6 In the UK, metformin was prescribed
to 45% of newly diagnosed T2DM patients in 2000 and
this increased to 91% by 2013.2 Metformin-like com-
pounds occur naturally in the plant Galega officinalis,
and whilst it was used in medieval Europe to treat
a variety of conditions, the plant is highly toxic with
a potential to induce hypotension. The blood glucose-
lowering effect of the plant was first described in 1656
by Thomas Culpeper, but at that time it was difficult to
identify the ingredient that was responsible for these
effects. Subsequently, it was found that the herb is rich
in two compounds, guanidine and galegine. Whereas gua-
nidine was shown to exhibit anti-diabetic effects in ani-
mals, its toxicity made it unsuitable for clinical use, and
whilst galegine had a lower toxicity, it failed to deliver the
same significant anti-diabetic activity. In 1945, during the
development of paludrine, the antimalarial drug,7 it was
noticed that a portion of the new molecule had a distinct
resemblance to galegine and within two years paludrine
had been demonstrated to exert a reduction in blood glu-
cose concentrations in animal studies. Contemporaneously,
studies of synthetic guanidine analogues discovered
a compound referred to as “flumamine” and suggested
that it might act in patients with malaria by lowering
blood glucose, thereby reducing the ability of the malarial
parasite to survive.8 Subsequently, the anti-diabetic effect
of flumamine – which is today known as metformin – was
investigated in animals 9 and showed it had a powerful
glucose-lowering effect which led investigators to suggest
that because metformin appeared to be a “glucose eater” it
should be called “Glucophage” and also reported that its
precise mechanism of action remained relatively
unknown,10 an observation that is true today, despite
many ensuing investigations.
It is now becoming clear that not all of the effects of
metformin can be attributed to the reduction of glucose
production in the liver as originally thought and evidence is
emerging for a key role exerted in the gut as detailed later in
this review.11 There also appear to be variations in the under-
standing of how the drug works at a molecular level, depen-
dent upon dose administered and whether treatment is of an
acute or chronic nature. Metformin has been demonstrated to
have both AMP-activated protein kinase (AMPK)-dependent
and AMPK-independent actions, and also inhibit mitochon-
drial respiration possibly via inhibition of mitochondrial
glycerophosphate dehydrogenase and/or through the invol-
vement of a lysosomal mechanism.12,13
Subsequent to the discovery of metformin, other trials
were published on the structurally similar biguanides,
namely phenformin and buformin; however, the two
drugs were quickly withdrawn from clinical use as
a result of inducing lactic acidosis.14,15 Consequently,
there was concern that this might be a class effect which
impacted upon the immediate extensive use of metformin.
However, other research demonstrating the benefits of
metformin, without similar side effects, provided reassur-
ance of the safety of the drug,16,17 with the strongest
supportive evidence provided by the United Kingdom
Prospective Diabetes Study (UKPDS).13 This investigation
demonstrated the benefits of the drug not only in lowering
cardiovascular mortality but also in increasing overall
survival rate of those diabetic patients who were obese 18
and has more recently been shown to reduce cardiovascu-
lar morbidity in individuals with non-alcoholic fatty liver
disease.19
Metformin is thought to exert a number of biological
actions, reducing insulin resistance and lowering gluco-
neogenesis, and thereby appears to relieve some of the
metabolic defects observed in T2DM.20 It also delivers
a cardioprotective effect as well as anti-inflammatory and
anti-atherothrombotic effects,21–25 reducing the risk of
liver cancer in a dose-dependent manner 26 with a recent
Wakeman and Archer Dovepress
submit your manuscript | www.dovepress.com
DovePress


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
umbrella review of meta-analyses and systematic reviews
finding strong associations between metformin use
and reduced pancreatic and colorectal cancer risk.27
Unfortunately, despite having many beneficial effects for
overall health, metformin is not universally well tolerated
with the adverse effects primarily reported to be the result
of gastrointestinal (GI) intolerance. Approximately 88% of
newly diagnosed T2DM individuals reported one or more
symptoms of the GI tract,28 with the most common
reported being diarrhoea (62%), heartburn (52%), nausea
(47%), abdominal pain (36%), bloating (35%) and
retching (21%),29 with the mechanisms for these side
effects a result of the actions of the drug in the GI
system.30 However, these are infrequent, mild and typi-
cally dose-related and can cease after reduction in the dose
administered or removal of the drug.
This review investigates the possible impact that
metformin has on the status of certain vitamin and
minerals as well as that of the microbiome. The latter
area is of particular current relevance given the rapidly
expanding research and understanding of the effects gut
flora can exert on wellbeing. It further investigates
whether there might be a connection between metformin
and other medications commonly co-prescribed to dia-
betics for associated comorbidities and how this could
confound the diagnosis of the complication of diabetic
neuropathy.
Methods
Studies published in peer-reviewed journals were consid-
ered for inclusion in the current review. The methods
used and results obtained from the included papers were
required to be well described with appropriate data col-
lection and analysis performed. The following databases
were searched MEDLINE via Pubmed, Embase, Scopus,
CINAHL for the period 1978 to June 2019. The search
was restricted to articles in the English language, studies
performed on human subjects, but were not limited by
study design. The lists of references found in these
papers were assessed for relevant additional sources.
The following literature search used the terms (including
closely related words and synonyms): metformin com-
bined with microbiome and/or Vitamins A, C, D, E, B1,
B2, B3, B5, B6, B12, and folic acid, iron, magnesium,
selenium, zinc, H2RAs, PPIs and polypharmacy. This
review will focus on the impact of metformin on
Vitamins B1, B12, and D, folic acid, magnesium and the
microbiome due to literature suggesting there to be an
interaction between these subjects and metformin, with
a lack of evidence relating to the remainder of the micro-
nutrients searched.
Review of Studies Examining How
Metformin Affects the Status of Specific
Micronutrients and the Microbiome
Vitamin B1
Vitamin B1 (thiamine) acts as a coenzyme in neurotrans-
mission and low levels of this nutrient may have a role in
the development of certain diabetic complications.31
Phenformin has been reported to exhibit anti-thiamine
activity in animals,32–34 and as a result, it has been sug-
gested that a possible anti-thiamine effect of metformin
might contribute to some cases of metformin-associated
lactic acidosis, a rare condition, but one that has been
shown to have a mortality rate of 18–25%.35–37 It has
been proposed that metformin and phenformin inhibit
thiamine absorption through inhibition of the human thia-
mine transporter (THTR2) in the small intestine,38
a finding recently confirmed to be clinically relevant,39
particularly in at-risk populations. In patients with
T2DM, plasma thiamine concentrations have been demon-
strated to be reduced.40,41 The magnitude of these reduc-
tions can be as large as 76% and 75%, respectively,
compared to levels in healthy volunteers with renal clear-
ance of thiamine increased 16-fold in T2DM patients.40,41
Low thiamine concentrations have been correlated to
higher concentrations of soluble vascular adhesion mole-
cule-1 (sVCAM-1), a surrogate marker of potential vascu-
lar disease in some, but not all studies.40,41
Folic Acid
One hundred and fifty compounds make up the pteroilgluta-
mate family, commonly referred to as folate, and are involved
in purine base synthesis of DNA as well as being important
co-factors in the metabolism of homocysteine (Hcy) to
methionine.42 Research has found that folate concentrations
in plasma and red cells in diabetic individuals with both
proliferative diabetic retinopathy and non-proliferative reti-
nopathy were significantly lower than both healthy subjects
and diabetic patients without retinopathy.43 A randomised
control trial involving 16 weeks of metformin administration
to patients with T2DM has been shown to result in reduced
folate and vitamin B12 levels, which typically result in
a modest increase in Hcy,44 a result that was supported
subsequently.45 Individuals with T2DM have elevated risk
of cardiovascular disease which is exacerbated by the
Dovepress Wakeman and Archer
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presence of hyperhomocysteinemia which has been attribu-
ted to reduced folate concentration in addition to the vitamin
B12 deficiency as detailed later.46–49 Indeed, two studies
have demonstrated that folate supplementation reduces
endothelial dysfunction in T2DM thought to be associated
with hyperhomocysteinemia.50,51 A recent meta-analysis
found that folate supplementation in young and elderly popu-
lations of varying insulin resistance status might be beneficial
in terms of improving glucose homeostasis and reducing
insulin resistance, though there is insufficient data to deter-
mine whether it can reduce the development of T2DM.52
Interestingly, folate supplementation in isolation was found
to be approximately one-third as effective as metformin in
reducing insulin resistance and preventing T2DM52 in the
populations examined.
Vitamin B12
Vitamin B12 (cobalamine) is a water-soluble vitamin and
a cofactor for the conversion of Hcy to methionine and
is a co-enzyme involved in the synthesis of purine bases
and pyrimidine. Older individuals (median age 76 years)
with T2DM are more likely to be deficient in micronu-
trients such as Vitamin B12 than their younger counter-
parts (median age 59 years).53 A recent study on older
adults (>50 years) found that vitamin B12 and folate
deficiency were high and metformin use was the largest
predictor of vitamin B12 deficiency.54 Metformin
has been demonstrated to impair vitamin B12
absorption,44,55–59 and concentrations of the vitamin in
serum have been inversely correlated with both dose and
length of therapy with the medication.60 The possible
mechanisms that result in metformin-induced deficiency
of vitamin B12 in patients with T2DM are highlighted in
Box 1.
The literature suggests that anything from 10% to 30%
of those prescribed prolonged metformin experience
malabsorption of vitamin B12, with 6–9% of individuals
shown to progress to deficiency.49,60–63 Risk factors asso-
ciated with developing metformin-related vitamin B12
deficiency include vegetarian diet, older age, metformin
use for 3 years and a higher metformin dose,60 with a more
recent study additionally finding that males had a higher
incidence than females.64 One significant study demon-
strated that after 16 weeks of treatment with metformin,
diabetic patients had lower vitamin B12 concentrations in
comparison to participants not receiving this drug or non-
diabetic controls.50 Subsequent studies have reported that
metformin-treated patients experienced statistically signif-
icant reduced vitamin B12 concentrations compared to
those not prescribed the drug,62 in geriatric patients 65
and in individuals with or without microalbuminuria.66
The authors suggested that physicians should check the
vitamin B12 concentrations at baseline, and then continue
to monitor these levels and assess the nutritional status of
those prescribed metformin, and recommended supple-
mentation when appropriate.65
As well as observing a reduction in folate status, Sahin
et al also demonstrated that as little as 6 weeks’ treatment
with metformin reduced vitamin B12 levels and increased
homocysteine (Hcy) concentration.45 A longer-term pla-
cebo-controlled study found that vitamin B12 deficiency
absolute risk was 11.2% greater in the group treated with
metformin and the number needed to harm was 8.9 per 4.3
years.67 Similar observations have been reported in New
Zealand and Brazilian cohorts of T2DM patients taking
metformin, with age, dose, and duration of metformin
treatment identified as important factors in the depletion
of vitamin B12.
68,69 However not all researchers have
demonstrated an inverse association between vitamin B12
status and metformin treatment as exemplified by one
small study performed in Qatar.70 In contrast, a recent
meta-analysis indicated that after up to 4 months of use
of metformin, diabetic patients’ vitamin B12 levels were
reduced by an average of 57 ρmol.l−1. It concluded that
a significant proportion of people with T2DM could
develop B12 deficiency or borderline values as
a consequence of metformin treatment.71 The likelihood
that there may be a genetic perspective in the deficiency of
vitamin B12 induced by metformin has been explored by
one group with polymorphisms in genes such as methylene
tetrahydrofolate reductase (MTHFR) suggested as possible
candidates.72
Box 1 Suggested Mechanisms That Result in Metformin-Induced
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Chronic metformin treatment first became known as
a pharmacological cause of vitamin B12 deficiency within
a decade of it coming into use and more recently decreased
serum folate concentration has also been associated with its
administration.46,73–75 It is therefore suggested that metfor-
min use may be an agent of iatrogenic potential inducing
peripheral neuropathy exacerbation in individuals with
T2DM who have depressed Vitamin B12, as a result of
elevated fasting methylmalonic acid (MMA) and tHcy
levels.76–79 One group has identified these factors as also
contributing to diabetic retinopathy.80 A means of resolving
this situation is provided by studies which have shown that
malabsorption of vitamin B12 induced by metformin can be
reversed by oral supplementation of vitamin B12, even
whilst metformin treatment is continued.56,81–84 In these
circumstances, it is necessary to avoid folic acid supple-
mentation prior to Vitamin B12 treatment, because whilst
folic acid might reverse in part some of the haematological
abnormalities that result from deficiency of vitamin B12, it
cannot deliver similar effects with respect to neuropsychia-
tric symptoms. A recent study of older people (>50) found
that multivitamin use was associated with higher serum B12
levels in both those with and without diabetes and in met-
formin users was associated with serum B12 levels that
were 50% higher than those not supplementing.54 At pre-
sent, it is not known if supplementation with calcium could
potentially prevent metformin-induced deficiency of vita-
min B12. Hence this supplementary approach should not be
considered for this purpose until this potential role been
further elucidated.85 However, the rationale to support this
observation is well characterised, since the hydrophobic tail
of metformin can penetrate cell membranes, thereby alter-
ing potentials and hence displacing divalent cations such as
calcium which can affect adhesion of a number of sub-
stances to the membrane. In all DNA synthesising cells,
the cell surface TCII receptors are calcium-dependent, and
the drug may interfere with the delivery of vitamin B12 into
them.59
Vitamin D
A classical function of vitamin D is considered to be the
regulation of calcium absorption and management of
homeostasis of that mineral; however, there is growing
evidence of non-classical effects including influencing
cell proliferation, differentiation, apoptosis, immune func-
tion, genome stability and neurogenesis.86 Research indi-
cates that vitamin D deficiency is linked with obesity and
that it is also associated with both an elevated insulin
resistance and a decreased insulin secretion.85,87 In a
study of Dutch community-dwelling geriatric outpatients,
after adjustment for gender and age, statistically significant
negative associations were found between use of metfor-
min and vitamin D status, with those non-supplement
users of vitamin D having levels of the vitamin 14.4%
lower compared to controls.88 The authors of a separate
cross-sectional study suggest the impact of metformin on
lowering vitamin D levels may have been confounded by
use of supplements at the time of diagnosis.89 In contrast,
some recent studies have found vitamin D status to have
been unaffected by metformin use62 and a placebo-
controlled study found no effects of the drug at 4 or
16 months use in people with T2DM.90
Magnesium
As the fourth most abundant cation in the body, magnesium
plays an important physiological role due to its role as
a cofactor in over 400 enzymatic reactions, including those
involved in energy metabolism, such as carbohydrate oxida-
tion, glucose transport mechanisms, as well as insulin secre-
tion, activity and binding.91 Oral supplementation of
magnesium has been shown to improve glucose handling
and insulin sensitivity as well as reducing the progression
to diabetes from pre-diabetes.91 In T2DM, magnesium status
also appears to influence the progression of common comor-
bidities such as hypertension, atherosclerosis and chronic
kidney disease.92 Furthermore, in these patients, hypomag-
nesemia can result in accelerated renal decline and contri-
butes to a poorer disease progression and prognosis.93 Serum
levels of magnesium have been shown to be associated with
microvascular complications in T2DM and status and intake
of this mineral also influences blood glucose control in these
patients 94–96 This is further complicated as it appears there
are many underlying causes of hypomagnesemia, both unre-
lated and related to T2DM.97 However, reports suggest that
in comparison to those without T2DM, hypomagnesemia
occurs at an increased frequency of 13.5–47.7% amongst
patients with the condition, as opposed to 2.5–15% in their
non-diagnosed counterparts.98
Several reports with limited patient numbers from around
30–40 years ago first suggested patients treated with metfor-
min experienced reduced plasma magnesium levels.99 But
these findings conflicted with another small study which
reported that metformin increased total intra-erythrocyte
concentration of magnesium and decreased urinary magne-
sium elimination.100 A more recent study retrospectively
evaluated the relationship between hypomagnesemia and
Dovepress Wakeman and Archer
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medication in a hospital in-patient cohort. In only 16% of the
181 patients diagnosed with hypomagnesemia could specific
causes such as vomiting or chronic diarrhoea-be
identified.101 Of the remainder, 79% had taken proton
pump inhibitors and/or metformin and/or diuretics. The
authors proposed proton pump inhibitors as possible causa-
tive agents of hypomagnesemia, especially when used for
over one year or prescribed in conjunction with other med-
ications, such as diuretics or metformin that might also lower
magnesium status. Subsequently, a large cohort study of
nearly 400 T2DM patients investigated the possible effect
of medication on magnesium status.102 Here, 62% of patients
using metformin were reported to have reduced plasma mag-
nesium levels, as were 45% of those using proton pump
inhibitors and 8% of β-adrenergic receptor agonist users.
However, of all the medications examined, metformin was
most strongly statistically, significantly correlated with
reduced plasma magnesium concentration.102 In another
recent review, 700 veterans were divided into seven cohorts
according to a diagnosis of diabetes and the medications they
were prescribed and compared with a control group.103
Those with diabetes had significantly reduced magnesium
concentrations compared to counterparts without the diagno-
sis. A significant relationship between lower magnesium
levels was observed for those with hypertension, cardiovas-
cular disease, or using metformin. The authors noted that
greater monitoring and possible supplementation with mag-
nesium are required in PPI andMetformin users as polyphar-
macy is associated with hypomagnesia which may explain
some of the side effects of these drugs.104
Microbiome
The recommended oral daily doses of metformin typically
range between 1 and 2 g per day. Hence, given that the
reported bioavailability of the drug is around 50%-60%,
there is still a level of faecal recovery of 20%-30%, sug-
gesting a significant proportion remains available to interact
with GI microbiota.105 Despite there being high inter-
individual and inter-population variation in gut microbiota
composition, metformin could cause significant alterations
to gut bacteria.11 The enzyme glycerophosphate dehydro-
genase has an important role in carbohydrate metabolism in
bacteria. The inhibition of this enzyme by metformin
impairs the production of nicotinamide adenine dinucleotide
(NAD+) required for gluconeogenic reactions.106 This
activity could, therefore, affect many commensal micro-
organisms, such as Bacillus subtilis which utilise this
enzyme, thereby resulting in an overproduction in the
colon of d-lactate.107 Other colonic organisms which utilize
sugars residing in the colon such as Lactobacillus,
Bifidobacterium and Eubacterium species might also con-
tribute to d-lactate overproduction 108 and other colon
microbiota can also convert d-lactate to l-lactate, thereby
contributing to the plasma lactate pool.109 Additionally,
unabsorbed glucose or glucose polymers that appear in the
colon provide a substrate for lactate-producing bacteria 110
which contribute to further elevated levels of both d- and
l-lactic acid that can be absorbed into the circulation.
Hence, it is probable that the accumulation of lactic acid
in the colon might result in all or some of the GI side effects
of metformin, particularly in users that consume diets high
in sugars and starch.111 Moreover, the GI predominant
microbiome in type 2 diabetics appears to be rich in micro-
bial species that harvest sugars.112 Other functional changes
characterized by the bacterial dysbiosis typical of the con-
dition are elevated branched-chain amino acid metabolism,
along with elevated methane metabolism, enhanced degra-
dation of xenobiotics and stimulated sulphate reduction.113
It is known that perturbations in the microbiome can influ-
ence the production and absorption of nutrients, especially
B vitamins, and hence it is, therefore, possible, as discussed
above, these effects of metformin on the gut flora may
contribute to the observed effects on vitamin B12 status,
with other possible consequences yet to be identified. In
contrast, a recent metagenomic analysis suggests the
adverse intestinal effects of metformin may also be the
result of a relative increase in escherichia abundance.114
Further complicating the relationship between metformin
and gut microbiota is a recent study on mice that found
that some of the antidiabetic effects of metformin may be
mediated by positive alterations to the microbiome. Indeed,
it has been found that 1 g/day of metformin can shift the
microbiota after as few as 3 days of administration, result-
ing in reduced metabolic dysfunction.115 It is thought that
metformin alters the biota towards short-chain fatty acids
(SCFAs) producing bacteria, thereby increasing glucagon-
like peptide (GLP-1) or peptide YY (PYY) improving glu-
cose homeostasis and improving gut barrier integrity.116
Therefore, alterations to the gut microbiota appear to med-
iate some of the positive and potentially negative aspects of
metformin administration.
In order to investigate the relationship between metfor-
min and the microbiota, one group of researchers devel-
oped a modulator of the microbiome to attempt to shift the
GI microflora of that observed in T2DM to one more
typical of healthy individuals.112 The modulator contains
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specific ingredients that are proposed to stimulate popula-
tions of those commensal microbiota that produce short-
chain fatty acids (SCFA) as opposed to lactic acid, slowing
down the absorption of small molecules by intensifying
the viscosity of the contents of the lumen, strengthening
the barrier of the mucosa, sequestering the production of
bile salts and acids, and delivering a high level of antiox-
idant protection that buffers oxidative stress.112 It was
delivered as a dissolvable powder along with metformin
and compared with a placebo formulation containing the
same dose of drug. The metformin/modulator combination
delivered a significantly enhanced tolerance to metformin
compared to the placebo formulation. It also delivered
mean fasting glucose levels 20% lower than with the
metformin-placebo formulation, indicating no reduction
of the antidiabetic effects of the drug. Albeit a small-
scale study (n=10), it appears that the addition of
a modulator of the GI microbiome to metformin may
increase tolerance of the drug, particularly in metformin
intolerant patients. However, one challenge of this study is
that the modulator has many active ingredients, which
makes it difficult to ascribe which is/are having the effect
and thus the mechanism of action remains speculative.
Discussion
Diabetes, Neuropathy and Vitamin B12
Vitamin B12 is key in nucleic acid methylation,
S-adenosylmethionine and haemoglobin synthesis, and fat
and protein metabolism.117–119 Vitamin B12 deficiency
signs and symptoms appear to be very similar to
diabetic neuropathy and are considered to be clinically indis-
tinguishable (Box 2).
Most patients with diabetes are reported to experience
nervous system damage ranging from mild to severe forms
that resemble the signs and symptoms detailed in Box 1.120,121
A recent meta-analysis of 29 studies of over 50,000 patients
put the prevalence of neuropathy at 31.5% (95% confidence
interval 24.4−38.6%) in people with T2DM), but it is esti-
mated to develop in 50% of patients in their lifetime.122 Severe
painful peripheral neuropathy in those with T2DM can
increase the medical costs of treatment by four-fold compared
to those with T2DM but no neuropathy.123 Greater attention to
the role of deficiency of vitamin B12 in diabetic neuropathy in
recent years has been supported by the 2017 American
Diabetic Association position statement where serum B12
investigation is recommended to be considered to exclude
non-diabetic causes.124 Despite many foods being fortified
with vitamin B12 in Ireland, a recent study found that approxi-
mately 12% of the general, older (>50 years) population were
low or deficient in vitamin B12 and vitamin B12 injection and/
or supplementation were the greatest predictors of plasma
vitamin B12 concentration.54 Supplementation of vitamin
B12, singularly or together with other interventions, has been
shown to improve many symptoms of this condition. These
include enhanced cutaneous sensitivity, reduced paraesthesia,
pain and autonomic symptoms, as well as improvements in
ulnar median/motor sensory nerve conduction velocity and
lower-extremity epidermal nerve fibre density.125–131 As
early as 1969, Berchtold et al reported that patients prescribed
2–3 months of metformin treatment exhibited malabsorption
of vitamin B12.
75 Vitamin B12 deficiency has been reported to
occur at a rate of between 5% and 36% of metformin users,
with this broad incidence range attributed to cumulative drug-
induced B12 depletion as a result of the duration and dosage of
the medication.132–138 Furthermore, studies have shown that
lower levels of vitamin B12 and deteriorating diabetic neuro-
pathy in patients treated with metformin than in those mana-
ged with other medications commonly prescribed in the
condition.74,139 Some observers suggest that this neuropathy
may, in part, be the result of depletion of B12, and this might be
due to elevated levels of homocysteine and MMAwhich can
damage neurones140. This is not surprising since although
metformin is the primary biguanide used in the treatment of
T2DM, both phenformin and buformin have been demon-
strated to negatively affect vitamin B12 levels.
141,142 Thus,
a number of authors have examined the possibility that met-
formin might be the cause of a vitamin B12 deficiency and
subsequently directly responsible for peripheral neuropathy in
T2DM patients. One review in 2017 that examined evidence
from eight studies on the subject concluded that the wide




























Note: Data from these studies.120–122
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variety of study designs, durations and small sample sizes
made it difficult to reach a definitive conclusion.143 One
complicating factor is the ubiquity of metformin use in indi-
viduals with T2DM. Since most studies are cross-sectional, it
can be difficult to find an appropriate control with T2DM that
is not being prescribed metformin. A more recent study per-
formed in Saudi Arabia identified vitamin B12 deficiency to be
four times higher in metformin users compared to T2DM
patients not using the drug and suggested that metformin
doses of >2000 mg per day and duration of use of >4 years
to be especially important risk factors, but it too failed to
establish a direct link between use of the drug, induction of
vitamin deficiency and peripheral neuropathy.144 A more
recent meta-analysis by Yang et al examined metformin use
and neuropathy and found no association, highlighting similar
issues in terms of the lack of randomised controlled trials,
small sample size and varying study design as described
above.145 However, in contrast, a study performed in India
concluded metformin use to be associated with vitamin B12
deficiency and clinical neuropathy in T2DM patients.139 It
must be stated that metformin is a very effective drug in
terms of improving glycaemic control, which itself reduces
peripheral nerve damage and indeed several animal studies
have indicated that it can have non-glycaemic related anti-
neuropathic and neuroprotective effects.143 It seems likely that
these protective effects could be optimised if metformin-
induced vitamin B12 deficiency could be avoided.
Monitoring of Vitamin B12 in Patients
Prescribed Metformin
Given the possible negative impact of metformin on vita-
min B12 levels, monitoring of the status of individuals
receiving this treatment might appear prudent.
The vast majority of studies across a range of coun-
tries have found an association between metformin use
and vitamin B12 deficiency71,144–146 and potentially
neuropathy,147 though there are some exceptions.148 The
authors of these studies recommend that vitamin B12
status be assessed, both before and regularly after com-
mencement of metformin treatment,74,84,144,146 and for
peripheral neuropathy to be assessed even in the absence
of B12 deficiency.147 For T2DM patients with borderline
deficiency, screening is improved by serum homocysteine
or MMA measurements as these makers are more sensi-
tive and specific,71 though both of these assays are sig-
nificantly more expensive than serum B12.149 Results
from several meta-analyses identified that there are
groups with an increased risk of B12 deficiency, namely
those with pre-existing moderately low vitamin B12
levels71 or those aged ≥60 years, and/or on ≥2000 mg/
day metformin and/or ≥3 years of treatment.145 However,
they found that even those aged ≤60 years, taking
≤2000 mg/day metformin and for ≤1 year had signifi-
cantly reduced vitamin B12, indicating that this reduction
started early in treatment for all ages and even with low
doses.145 A complicating factor in determining metfor-
min-induced deficiencies is that there are large vitamin
B12 stores in the liver and these can take up to five years
to manifest as a deficiency.150 The American Diabetes
Association’s position stand on diabetic neuropathy states
that non-diabetic causes should be excluded by consider-
ing “undertaking a family and medication history and
performing relevant investigations e.g. serum B12, folic
acid. . ..”, but it makes no mention of metformin specifi-
cally and provides no recommendations for frequency of
screening.124 The British Society of Haematology pub-
lished its guidelines on vitamin B12 and folate screening
in 2014, at which time they stated that “no definitive
advice can be given on the desirable frequency of mon-
itoring” of vitamin B12 in those with T2DM having
metformin therapy but recommended that serum B12 be
measured “in the presence of strong clinical suspicion of
deficiency”,149 which we would opine may be difficult
since deficiency is often asymptomatic. For those where
metformin is determined as a cause of reduced serum
vitamin B12, they recommend oral supplementation of
50 μg for one month and monitoring at 6 months and then
yearly intervals, but could not advise on prophylactic
administration in those taking metformin. Thus, consen-
sus screening frequencies have not been established,
though some recommend initial baseline testing and at
subsequent intervals of no more than 1–2 years.74
Screening and monitoring of vitamin B12 status are not
routinely performed in those being administered metfor-
min and the authors propose that it should, particularly
since deficiencies are frequently asymptomatic and neu-
ropathy is frequently irreversible. Clinicians should be
aware of the potential benefits of screening in those
who are older, have been on metformin for >3 years,
are going on to high doses of metformin or who have
neuropathic symptoms. It should be noted that there is
a lack of research assessing the cost–benefit analysis of
periodic monitoring of vitamin B12 in those taking met-
formin, though it is a relatively inexpensive test to
undertake.150
Wakeman and Archer Dovepress
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T2DM and Gastroesophageal Reflux
Disease (GORD)
Commonly, the T2DM population has an increased BMI
which is well recognised to be associated with symptoms of
GORD.151,152 However, an increased BMI in these patients is
not alone as a risk factor in the development of GORD, as
peripheral neuropathy has also been identified as a separate
independent risk factor for erosive oesophagitis.153 Amongst
these individuals, a greater incidence of erosive esophagitis is
observed in thosewith neuropathy than amongst thosewithout,
despite both experiencing similar GORD symptoms. A recent
meta-analysis of cross-sectional studies involving 9067 cases
and 81,968 controls found a significant association between
T2DM and GORD (odds ratio 1.61).154 Around 60–70% of
diabetics have grades of nervous system damage, from mild
through to severe forms, which may partly explain why indi-
viduals with diabetes experience twice the incidence of low-
grade oesophageal dysplasia as non-diabetics.155 In addition,
symptomatic and asymptomatic reflux occursmore commonly
in those with T2DM. Moreover, the condition is known to be
a risk factor for symptomatic GORD.156–158 Amongst T2DM
patients, 40% are reported to suffer from symptomatic GORD,
and of these, 70% are prescribed oral antidiabetic
treatments.157 Therefore, it is possible that millions of patients
are managing these comorbidities concomitantly with oral
medications such as metformin along with either/or PPIs or
H2RAs. Hence, it is worthwhile considering the likely clinical
consequences and drug interactions and that might potentially
occur as a result of this common co-prescription scenario.
Histamine H₂ Receptor Antagonist (H2RA)/
Proton Pump Inhibitor (PPI) –Induced
Vitamin B12 Depletion
Literature suggests that drugs which suppress stomach acid
production such as PPIs159–163 andH₂RAs164–167 interferewith
vitamin B12 absorption, by reducing dietary B12 release from
food proteins. A 53–89% reduction in protein-bound B12
absorption was noted following H₂RA treatment,159,162 with
ranitidine specifically reported to induce decreases in B12
status.168–171 Similarly, there have been other reports of an
inverse correlation between vitamin B12 levels and duration
of PPI therapy.172–175 The enzyme cytochrome P450 2C19
(CYP2C19), catalyses the metabolism of PPIs and
a polymorphism of this enzyme has been demonstrated to
influence levels of vitamin B12 in patients using these
medications.173 Hence, those who poorly metabolize PPIs are
likely to exhibit increased suppression of acid production and
thus more interference with absorption of vitamin B12.
Alternatively, patients who have enhanced PPI metabolism
are likely to experience diminished acid suppression with
a lower interference with absorption of B12.
A number of studies have ascribed this effect to
a combination of reduced secretion of IF, gastric acid and
pepsin.174,175 In cases of vitamin B12 depletion induced by
H₂RA medications, levels of the vitamin have improved as
a result of oral vitamin B12 supplementation (as opposed to
food source vitamin B12 ingestion) as well as discontinuation
of H2RA therapy.162,166,168,176 In the case of PPI-induced B12
depletion, vitamin B12 supplementation, potentially above
recommended daily allowance levels has been demonstrated
to be effective.165,167 A 2015 meta-analysis and systematic
review examined the long term (≥10 months) association
between the development of vitamin B12 depletion and use
of PPIs and H₂RAmedications.177 Five studies met the criteria
for inclusion – four were case controlled, evaluating over
23,000 subjects and the other an observational study.
However, they all differed in the methodology and criteria
used to identify vitamin B12 deficiency as well as in the
definition used.159–161,163,178 In these four studies,
a significantly increased risk of developing vitamin B12 deple-
tion as a result use of acid-lowering medication was identified
and data from the two studies evaluating duration of treatment
supported the general assumption that long-term use of these
drugs is associated with an elevated risk of deficiency of this
vitamin, but the results were not conclusive.
Apart from the effects of these medications on vitamin
B12 status, drugs that inhibit acid secretion have been
observed to have negative impacts on the status of certain
other micronutrients and the microbiome. PPIs specifically
have been shown to cause irregularities in magnesium
status, small intestinal bacterial overgrowth and enteric
infections including clostridium difficile, resulting in
a 20% difference in bacterial taxa compared to non-users
of these drugs which favours streptococcal abundance
irrespective of H.pylori status.179–182
Clinical Issues Around Metformin Use
and Vitamin B12 Status: Polypharmacy and
Treatment Strategies
In light of the increasing prevalence of obesity, T2DM and
GORD, there exists a potential for greater concomitant use
of acid-suppressing medications alongside antidiabetic
treatments. Since monotherapy with metformin, PPIs, or
H₂RAs, has been demonstrated to significantly deplete
Dovepress Wakeman and Archer
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vitamin B12 independently, co-prescription of these medi-
cations might induce an additive effect. This has been
observed in clinical practice where 34% of patients co-
prescribed metformin alongside PPIs were vitamin B12
deficient, significantly greater than those on metformin
(22%) or PPIs (26%) monotherapy, suggesting an additive
effect.183 It is therefore important to recognise the poten-
tial likelihood of neuropathy induced by vitamin B12,
occurring or being exacerbated as a result of the co-
prescription of medications commonly used to treat these
co-morbidities, particularly since they are typically long-
term drug treatments. Awareness of this issue by medical
professionals, specifically pharmacists, is particularly
important because of the common frequency of exposure
of the diabetic population to both metformin and either
PPIs or H2RAs, especially since the two latter medications
are readily available as over-the-counter versions. Given
that T2D patients have up to 60–70% likelihood of experi-
encing diabetic neuropathy, what might sometimes be
considered to be “diabetic” neuropathy may, at least in
part, be a neuropathy induced by vitamin B12 deficiency as
a consequence of concomitant use of metformin alongside
PPI/H₂RAs.
An evaluation of the issues associated with the use of
metformin and vitamin B12 status that are clinically rele-
vant and significant to most healthcare practitioners
appeared in an editorial in The New Zealand Medical
Journal entitled – “A safe and effective drug?”.176 It
noted that whilst formularies identify vitamin B12 defi-
ciency as a possible side effect of metformin, there is
a lack of guidance relating to the investigation of the
risk, despite there being a deficiency prevalence of 17%
in the study cited in the editorial.68 It further suggests that
unlike GI side effects of metformin which can be readily
identified, early vitamin B12 deficiency is asymptomatic
and hence unlikely to be diagnosed. However, when it
does become manifest, it presents as a peripheral neuro-
pathy which is also a complication of diabetes making it
less likely to be diagnosed by symptoms alone. It con-
cludes that whilst the neurological effects of this defi-
ciency are permanent, its presence at an early stage can
be detected with readily and cheaply available diagnostic
tools, and reversed with effective supplementation.
Common patient information leaflets underplay the
incidence of metformin-induced vitamin B12 deficiency,
stating that the risk of this “rare side effect” is 1:10,000.184
A UK community practice study reported that only 36% of
patients using metformin had their vitamin B12 levels
checked and had this assessment added to the yearly recall,
despite the test being relatively inexpensive and adding
little extra burden on patient or appointment
availability.185 Authors have reported that decreased
serum levels of vitamin B12 levels in T2DM patients
treated with metformin can be corrected by either sublin-
gual methylcobalamin supplements or hydroxocobalamin
injections.82,132,186 Indeed, the British Association for
Haematology recommends that in cases of Vitamin B12
deficiency, intramuscular injections of 1000 μg should be
administered three times per week for two weeks in indi-
viduals without neurologic deficits and every other day for
three weeks in those with neurological deficits. However,
since major drawbacks of intramuscular injections are the
general need for medical personnel to perform the inter-
vention and the fact that they are sometimes painful,187
oral supplementation appears preferable in the absence of
severe deficiency, except when poor absorption is
expected. The British Association for Haematology sup-
ports oral supplementation in those without severe defi-
ciencies, malabsorption syndromes or compliance issues.
Not every study has demonstrated that oral B12 supple-
mentation reduces the risk of deficiency in metformin
users, which the researchers indicated may be explained
because the dose of 0.6 μg typically found in multivitamin
supplements is inadequate for those on metformin treat-
ment in terms of prophylaxis,56 whereas other studies have
found that multivitamin use was associated with reduced
risk of deficiency.134,188 Other researchers propose strate-
gies to correct vitamin B12 deficiency which are similar to
the British Association for Haematology’s position state-
ment at 1000 μg daily doses orally or via intramuscular
injections for a week followed by once per week for four
weeks to correct this deficiency.189 In contrast, from
a prophylactic approach, another research group proposed
what they deemed a cost-effective approach of yearly
injections of 1000 μg of vitamin B12 to every patient on
metformin to reduce the risk of deficiency and also stated
that this could remove the requirement for annual screen-
ing, though this has not been empirically tested.
Additionally, Swedish researchers recommend that to opti-
mally benefit from medication with metformin, morbidly
obese patients should undergo routine assessments of both
vitamin B12 and magnesium levels, with relevant supple-
mentation considered where necessary to maintain optimal
status.190 As detailed earlier in this review, the recommen-
dation that calcium supplementation could potentially
Wakeman and Archer Dovepress
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prevent metformin-induced deficiency of vitamin B12 is
premature due to the existing paucity of studies.59
Conclusion
That metformin is generally a safe, effective and inexpen-
sive first-line therapy in the treatment of T2DM is unques-
tionable. In addition, recent research indicates that it may
partially mediate its antidiabetic properties through altera-
tion to the gut microbiota. However, this review provides
evidence that its use can impact upon the status of vita-
mins B1, B12, D, folic acid and magnesium as well as
causing disruption to the microbiome, all of which may to
some extent predicate the desired outcomes with this
medication. Given that the status of these micronutrients
in patients with T2DM is already likely to be suboptimal
and that these deficiencies are variously associated
with diabetic complications such as compromised
endothelial, microvascular, vascular and neurological
function,38,43,46–49,80,85,95–97 it may be appropriate to con-
sider supplementation where appropriate to mitigate these
negative impacts of metformin. Since elderly T2DM
patients are likely to experience greater prolonged expo-
sure to both metformin and polypharmacy involving other
drugs that are known to negatively impact upon micronu-
trient status makes the monitoring and management of this
group particularly important. In many cases, this could be
easily prevented by a simple supplementation approach,
particularly as vitamin B12 has low toxicity. A greater
number of randomized controlled trials as opposed to
cross-sectional studies are required to conclusively iden-
tify the extent to which H2RAs, PPIs and metformin
independently and in combination contribute to patients’
increased risk of vitamin B12 deficiency and potentially
consequent neuropathy. Until then, it would be reasonable
for physicians prescribing metformin singly or in combi-
nation with these drugs to monitor the patient’s vitamin
B12 status and to prescribe vitamin B12 supplements if
blood biomarkers or clinical symptoms are consistent with
a low vitamin B12 status.
191
Ultimately, the cost of drug treatment-even with the
most apparently safe and effective of drugs, such as met-
formin-is not simply the price of that treatment. Awareness
of, monitoring and practical management of the possible,
often underappreciated, side effects are necessary to miti-
gate patient harm and deliver optimal management of the
condition.
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